endo_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
|
|
|
|
|
Date of Report (Date of Earliest
Event Reported):
|
|
May 1, 2008 (April 29, 2008)
|
Endo Pharmaceuticals Holdings
Inc.
_________________________________________
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-15989
|
|
13-4022871
|
|
_____________________
(State or other
jurisdiction
|
|
_____________
(Commission
|
|
______________
(I.R.S.
Employer
|
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
|
|
|
|
|
|
|
100 Endo Boulevard, Chadds Ford,
PA
|
|
|
|
19317
|
|
_________________________________
(Address of principal
executive
offices)
|
|
|
|
___________
(Zip
Code)
|
|
|
|
|
|
Registrant’s telephone number, including area
code
|
|
(610)
558-9800
|
Not Applicable
_____________________________________________
Former name or former address, if
changed since last report
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item
5.02 Departure of Directors of Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On
April 29, 2008, Michel de Rosen notified Endo Pharmaceuticals Holdings Inc. (the
"Company") of his intent to not stand for reelection as a director of the
Company at the Company's 2008 Annual Meeting of Stockholders so that he may
devote more time to his new position as Chief Executive Officer of Saint-Gobain
Desjonqueres in France, a position he has held since March 31,
2008. Mr. de Rosen will continue to serve as a director of the
Company until the expiration of his term at the Company's 2008 Annual Meeting of
Stockholders.
On
April 29, 2008, Dr. David A.H. Lee, M.D., Ph.D., notified the Company that he
was resigning his position as Chief Scientific Officer, effective April 30,
2008, to devote more time to pursue his philanthropic activities. Dr.
Lee, who has been working part-time for the Company for over a year, has agreed
at the Company’s request to remain with the Company as a senior strategic
adviser primarily to continue to support the Company’s activities in the area of
public affairs.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
|
ENDO
PHARMACEUTICALS HOLDINGS INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/
Caroline B. Manogue
|
|
|
|
|
Name:
|
Caroline
B. Manogue
|
|
|
|
Title:
|
Executive
Vice President, Chief Legal Officer & Secretary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dated: May
1, 2008